NEWS - Jun 10, 2015 Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone Read more
NEWS - May 27, 2015 Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference Read more
NEWS - May 12, 2015 Relmada Therapeutics Announces Notice of Allowance for U.S. Patent Covering SECUREL(TM), its Abuse-Deterrent, Extended-Release, Technology Platform for Opioids Read more
NEWS - Apr 21, 2015 Relmada Therapeutics Commences Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Read more
NEWS - Apr 16, 2015 Relmada Therapeutics Receives Health Canada Clearance to Further Explore Promising NMDA Receptor Antagonist d-Methadone (REL-1017) Read more
NEWS - Apr 8, 2015 Relmada Therapeutics Appoints Lisa Nolan, Ph.D. as Senior Vice President of Business Development Read more
NEWS - Apr 2, 2015 Relmada Therapeutics Set for Busy 2015 in Clinical Trials Developing Drugs for the Lucrative Pain Market Read more
NEWS - Mar 24, 2015 Relmada Therapeutics Receives Health Canada Clearance to Commence First Clinical Study for Novel Oral Formulations of Buprenorphine Read more
NEWS - Mar 17, 2015 Relmada Therapeutics Reports Positive Phase 1 Results for NMDA Receptor Antagonist d-Methadone Read more
